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A bs tr ac t
Background
Long-acting beta-agonist (LABA) therapy improves symptoms in patients whose asth-
ma is poorly controlled by an inhaled glucocorticoid alone. Alternative treatments 
for adults with uncontrolled asthma are needed.
Methods
In a three-way, double-blind, triple-dummy crossover trial involving 210 patients with 
asthma, we evaluated the addition of tiotropium bromide (a long-acting anticholin-
ergic agent approved for the treatment of chronic obstructive pulmonary disease 
but not asthma) to an inhaled glucocorticoid, as compared with a doubling of the 
dose of the inhaled glucocorticoid (primary superiority comparison) or the addition 
of the LABA salmeterol (secondary noninferiority comparison).
Results
The use of tiotropium resulted in a superior primary outcome, as compared with a 
doubling of the dose of an inhaled glucocorticoid, as assessed by measuring the 
morning peak expiratory flow (PEF), with a mean difference of 25.8 liters per min-
ute (P<0.001) and superiority in most secondary outcomes, including evening PEF, 
with a difference of 35.3 liters per minute (P<0.001); the proportion of asthma-
control days, with a difference of 0.079 (P = 0.01); the forced expiratory volume in 
1 second (FEV1) before bronchodilation, with a difference of 0.10 liters (P = 0.004); 
and daily symptom scores, with a difference of −0.11 points (P<0.001). The addition 
of tiotropium was also noninferior to the addition of salmeterol for all assessed 
outcomes and increased the prebronchodilator FEV1 more than did salmeterol, with 
a difference of 0.11 liters (P = 0.003).
Conclusions
When added to an inhaled glucocorticoid, tiotropium improved symptoms and lung 
function in patients with inadequately controlled asthma. Its effects appeared to be 
equivalent to those with the addition of salmeterol. (Funded by the National Heart, 
Lung, and Blood Institute; ClinicalTrials.gov number, NCT00565266.)
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Many adults with asthma have in-adequate control of symptoms when re-ceiving a low-to-medium dose of an in-
haled glucocorticoid.1,2 Treatment options include 
the addition of a leukotriene modifier,2 the addi-
tion of a long-acting beta-agonist (LABA),2-4 or an 
increased dose of an inhaled glucocorticoid.2 Cur-
rent guidelines of the National Asthma Education 
and Prevention Program favor the last two op-
tions.2 In recent communications, however, the 
Food and Drug Administration (FDA)5 and asth-
ma experts6,7 have questioned the safety of LABA 
therapy and suggested strategies to minimize the 
use of these drugs. Because of such concerns and 
the heterogeneity of patients with asthma, alter-
native controller agents are needed.
Whether anticholinergic agents are useful for 
asthma management is not clear. A Cochrane Re-
view reported that there is no justification for 
routinely introducing anticholinergic agents (the 
report focused on ipratropium bromide), while ac-
knowledging that the role of long-acting anticho-
linergic agents such as tiotropium bromide has 
not been established.8 Tiotropium has a duration 
of action of more than 24 hours9,10 and was ap-
proved by the FDA for the treatment of chronic 
obstructive pulmonary disease (COPD) in January 
2004. However, tiotropium has not been approved 
for the treatment of asthma.
In a double-blind, three-way, crossover trial, 
called the Tiotropium Bromide as an Alternative 
to Increased Inhaled Glucocorticoid in Patients 
Inadequately Controlled on a Lower Dose of In-
haled Corticosteroid (TALC) study, we tested two 
hypotheses. The primary hypothesis stated that in 
patients with asthma that is inadequately con-
trolled by an inhaled glucocorticoid alone, the ad-
dition of tiotropium bromide would be superior 
to a doubling of the dose of an inhaled glucocor-
ticoid. The secondary hypothesis stated that in 
such patients, the addition of tiotropium would 
not be inferior to the addition of a LABA. We 
evaluated the primary outcome, the morning peak 
expiratory flow (PEF), as well as additional out-
comes, in 210 patients with asthma inadequate-




Beginning in June 2007, we enrolled 826 patients 
in a common run-in period for two asthma stud-
ies. One of the studies, called the Best Adjustment 
Strategy for Asthma over Long Term (BASALT) 
trial (ClinicalTrials.gov number, NCT00495157), 
involved patients with mild-to-moderate disease, 
and the results are not reported here. A total of 
342 patients underwent randomization in the 
BASALT study, 210 patients underwent random-
ization in the TALC study (with the last patients 
completing the study on May 21, 2010), and 274 
patients were excluded from both studies (Fig. 1). 
The inclusion criteria for enrollment in the com-
mon run-in period for both studies included an 
age of at least 18 years, a history of asthma con-
firmed by bronchodilator reversibility or bronchi-
al hyperresponsiveness, a forced expiratory vol-
ume in 1 second (FEV1) of more than 40% of the 
predicted value, and nonsmoking status (<10 pack-
years). Exclusion criteria are listed in the Supple-
mentary Appendix, available with the full text of 
this article at NEJM.org.
The study was approved by the committee on 
human research at each institution. All patients 
provided written informed consent.
Study Protocol
At the onset of the 4-week run-in period, all pa-
tients were treated with a hydrofluoroalkane me-
tered-dose inhaler of beclomethasone (Qvar) at a 
dose of 80 μg (2 puffs of 40 μg) twice daily (Fig. 2, 
and Fig. S1 in the Supplementary Appendix). All 
other asthma medications were stopped. Patients 
were eligible for assignment to either the TALC 
study or the BASALT study if at week 4 they had 
at least 75% adherence to the run-in protocol (as 
shown by peak flow, diary card, and study medi-
cations), an FEV1 of more than 40% of the pre-
dicted value, and no need for additional asthma 
medications. Patients were assigned to the TALC 
study if at week 4 they had no medical contrain-
dication to tiotropium and the FEV1 was 70% or 
less of the predicted value or if during the final 
2 weeks of the run-in period they had symptoms 
6 or more days per week or used a rescue inhaler 
6 or more days per week or were awakened by 
symptoms of asthma two nights or more per week.
Weeks 3 and 4 of the run-in period provided 
baseline data for the first treatment period and 
inflammatory biomarkers. Patients were treated 
for a 14-week period with the run-in dose of bec-
lomethasone plus inhaled tiotropium bromide 
(Spiriva HandiHaler) at a dose of 18 μg every 
morning plus a salmeterol placebo inhaler; 160 μg 
(2 puffs of 80 μg) twice daily of beclomethasone 
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(i.e., a doubling of the run-in dose) plus a tiotro-
pium placebo inhaler and salmeterol placebo in-
haler; or the run-in dose of beclomethasone plus 
salmeterol xinafoate (Serevent Diskus) at a dose 
of 50 μg twice daily plus a tiotropium placebo 
inhaler. Between each treatment, there was a 
2-week washout period during which patients re-
ceived only the run-in dose of beclomethasone to 
652 Were eligible for assignment
826 Patients were enrolled in common
run-in, starting in June 2007
174 Were excluded during common run-in
54 Withdrew consent
16 Were lost to follow-up
1 Had drug-related adverse event
1 Had adverse event not related to asthma
or drugs
59 Had a compliance issue
9 Had asthma exacerbation
19 Were ineligible
15 Had other reason
363 Were assigned to BASALT,
starting in July 2007
289 Were assigned to TALC,
starting in July 2007
79 Were excluded before TALC randomi-
zation
57 Were assigned before TALC start date
22 Were assigned after TALC recruitment
 closed
21 Were excluded before BASALT randomi-
zation
9 Withdrew consent
1 Was lost to follow-up
7 Had compliance issues
2 Were assigned in error
2 Had other reason
342 Underwent randomization to
BASALT by October 2009
210 Underwent randomization to TALC
by June 2009
174 Completed TALC by May 2010
phase
23 Withdrew consent
7 Were lost to follow-up
2 Had drug-related adverse event
1 Was found to be ineligible at visit 3
3 Had other reason
23 Dropped out in TALC period 1
5 Dropped out in TALC period 2
8 Dropped out in TALC period 3
0 Dropped out during TALC washout period
7 Dropped out while receiving tiotropium
14 Dropped out while receiving double-
glucocorticoid
15 Dropped out while receiving salmeterol
36 Dropped out during TALC treatment
Figure 1. Enrollment and Outcomes.
The TALC and BASALT studies were companion trials that used a common run-in period: patients with better-con-
trolled asthma were assigned to the BASALT trial, and those with poorer control were assigned to the TALC trial. 
Shown are the numbers of patients who enrolled in the common run-in period, those who underwent randomiza-
tion to each study, and those who completed the TALC study. At the start of the recruitment period, TALC study 
drugs were not yet available, which accounted for the 57 patients who were assigned before the TALC start date, and 
randomization of patients to the TALC trial ended before all patients were assigned to the BASALT trial, which ac-
counted for the 22 patients who were assigned after TALC recruitment closed.
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establish baseline data for the next period. The 
study was conducted in accordance with the pro-
tocol, which is available at NEJM.org.
Outcome Measures
The predetermined primary outcome measure was 
the morning PEF. Predetermined secondary out-
come measures included the FEV1 before bron-
chodilation, the number of asthma-control days 
(defined as days without symptoms and without 
the use of a rescue bronchodilator), asthma symp-
toms, rescue-bronchodilator use, asthma exacer-
bations (defined as increased asthma symptoms 
resulting in the use of oral glucocorticoids or the 
increased use of inhaled glucocorticoids or other 
asthma medications), use of health care services, 
biomarkers of airway inflammation, and results 
of validated questionnaires, including the Asthma 
Control Questionnaire,11,12 the Asthma Symptom 
Utility Index,13 and the Asthma Quality-of-Life 
Questionnaire.14 (For all questionnaires, the rang-
es, interpretations, and minimal clinically signifi-
cant differences are presented in Table 1 and in 
the Supplementary Appendix.) Additional prespeci-
fied exploratory hypotheses are listed in the Sup-
plementary Appendix.15 Also prespecified was an 
analysis of patients’ responses to the various study 
drugs, singly and in combination (a responder 
analysis).16,17
Study Oversight
The study was funded by the National Heart, Lung, 
and Blood Institute. The protocol was approved 
by the protocol review committee of the institute’s 
Asthma Clinical Research Network and monitored 
by the network’s data and safety monitoring 
board. Tiotropium was used under the provisions 
of an approved application for an investigational 
new drug, submitted by the network’s data coor-
dinating center. Beclomethasone canisters con-
taining either 40 μg or 80 μg and rescue albuterol 
(Pro-Air) were supplied by Teva Specialty Phar-
maceuticals. Tiotropium and matching placebo 
were supplied by Boehringer Ingelheim Pharma-
1 5 109876432 11 12 13 14 15
Visits
































Figure 2. Outline of Study Protocol.
Shown are the durations of the common run-in, treatment, and washout periods, along with periods in which base-
line data for variables that were collected daily were obtained before each treatment period. During the 4-week run-
in period and the 2-week washout periods, all patients received beclomethasone at a dose of 80 μg (2 puffs of 40 μg) 
twice daily. Only three of the six possible treatment sequences are presented graphically.
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ceuticals, which had the opportunity to comment 
on the study design. This input resulted in an in-
crease in the sample size to include more patients 
with the Arg/Arg polymorphism in the gene en-
coding the β2-adrenergic receptor. The company 
had no role in the performance of the trial, the 
analysis or interpretation of the data, the prepa-
ration of the manuscript, or the decision to submit 
the manuscript for publication. Salmeterol and 
matching placebo were purchased from third-party 
vendors. Medication use was measured by means 
of an electronic device (for beclomethasone), a 
counter for dry-powder inhalers (for salmeterol), 
and assessment of used blister packs (for tiotro-
pium), with mean (±SD) rates of compliance of 
84.1±16.2%, 92.6±12.3%, and 93.0±12.2%, re-
spectively.
The informed-consent document was amend-
ed in April 2008 to acknowledge the FDA’s Med-
Watch alert regarding the association between 
Table 1. Baseline Characteristics of the 210 Patients.*
Characteristic Value
Male sex — no. (%) 69 (32.9)
One or more positive skin tests for atopy — no./total no. (%) 175/200 (87.5)
Age at visit 1 — yr 42.2±12.3
Duration of asthma — yr 26.1±14.1
Weight at visit 1 — kg 88.3±25.3
Body-mass index at visit 1† 31.4±8.8
FEV1
Value at visit 3 before bronchodilation — liters 2.31±0.77
Percent of predicted value at visit 3 before bronchodilation 71.5±14.9
Percent reversal of obstruction with albuterol (4 puffs) at visit 3 14.9±9.8
Value after albuterol (4 puffs) at visit 3 — liters 2.64±0.82
Percent reversal of obstruction with ipratropium (4 puffs) at visit 2 12.4±9.5
Value after ipratropium (4 puffs) at visit 2 — liters 2.62±0.80
PEF before visit 3 (2-wk mean) — liters/min
Morning 377.2±117.0
Evening 383.6±119.0
Daily-symptom score before visit 3 (2-wk mean)‡ 0.46±0.44
Albuterol rescue use before visit 3 (2-wk mean) — puffs/day 1.71±2.09
Asthma-control days before visit 3 (2-week mean)
Proportion of days 0.212±0.331
No. of days 2.97±4.64
Asthma Control Questionnaire score at visit 3§ 1.64±0.73
Asthma Quality-of-Life Questionnaire score at visit 3¶ 5.43±1.05
Asthma Symptom Utility Index score at visit 3‖ 0.78±0.15
Geometric mean exhaled nitric oxide at visit 3 — ppb (coefficient of variation) 18.8 (0.7)
* Plus –minus values are means ±SD. FEV1 denotes forced expiratory volume in 1 second, and PEF peak expiratory flow.
† The body-mass index is the weight in kilograms divided by the square of the height in meters.
‡ Daily symptoms were evaluated on a scale from 0 to 3, with a higher score indicating a greater severity of symptoms.
§ Scores on the Asthma Control Questionnaire range from 0 to 6, with a higher score indicating worse asthma control; 
the minimal clinically important difference (MID) is 0.5.
¶ Scores on the Asthma Quality-of-Life Questionnaire range from 1 to 7, with a higher score indicating a better quality  
of life; the MID is 0.5.
‖ Scores on the Asthma Symptom Utility Index range from 0 to 1, with a higher score indicating better asthma control; 
the MID is unknown, but a difference of 0.3 is suggested to distinguish between mild-to-moderate and moderate-to- 
severe asthma.
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tiotropium and the risk of stroke. No patient with-
drew because of this modification.
Statistical Analysis
The primary hypothesis was that the addition of 
tiotropium to an inhaled glucocorticoid would be 
superior to a doubling of the dose of the inhaled 
glucocorticoid with respect to the morning PEF. 
The secondary hypothesis was that the addition 
of tiotropium to an inhaled glucocorticoid would 
not be inferior to the addition of salmeterol with 
respect to the morning PEF, the prebronchodilator 
FEV1, and the proportion of asthma-control days. 
All analyses were performed according to the in-
tention-to-treat principle.
The original target sample size of 224 patients 
was reduced in May 2009 to 210 patients, which 
provided a power of 90% for detecting a between-
treatment difference of 10.6 liters per minute in 
the morning PEF on the basis of a one-sided sig-
nificance level of 0.025, allowing for a dropout 
rate of 10%. This effect size was chosen because 
of the comparison between the addition of tiotro-
pium to an inhaled glucocorticoid and the dou-
bling of the dose of an inhaled glucocorticoid, 
an active control. The study also had a power of 
90% to detect a between-treatment difference in 
the proportion of asthma-control days of 0.07 
and a power of 93% to detect a between-treatment 
difference in the prebronchodilator FEV1 of 0.09 
liters.
Descriptive statistics were counts and percent-
ages for categorical variables, means and standard 
deviations for normally distributed variables, geo-
metric means and coefficients of variation for 
normally distributed log-transformed variables, 
and medians and first and third quartiles for 
variables that were not normally distributed on 
the original or log-transformed scales.
A linear mixed-effects model was applied to 
crossover data for each continuous outcome vari-
able.18-20 Fixed-effects terms included clinical 
center (stratifying variable), treatment regimen, 
treatment sequence, treatment period, and ho-
mogeneous carryover effects. Evaluation of clin-
ical outcomes was performed at weeks 0, 4, 9, and 
Table 2. Outcome Variables.*
Variable Mean Change from Baseline
Tiotropium P Value Double-Glucocorticoid P Value Salmeterol P Value
Morning PEF — liters/min 24.4 (16.0 to 32.7) <0.001 −1.4 (−8.4 to 5.6) 0.69 18.0 (11.5 to 24.5) <0.001
Evening PEF — liters/min 29.6 (21.9 to 37.3) <0.001 −5.7 (−12.3 to 0.9) 0.09 19.0 (11.7 to 26.3) <0.001
Albuterol rescue use  
— puffs/day
−0.11 (−0.26 to 0.03) 0.12 −0.07 (−0.19 to 0.06) 0.30 −0.16 (−0.28 to −0.03) 0.01
Mean daily-symptom score −0.09 (−0.12 to −0.05) <0.001 0.03 (−0.01 to 0.06) 0.11 −0.04 (−0.08 to −0.01) 0.02
Proportion of asthma- 
control days
0.131 (0.090 to 0.171) <0.001 0.051 (0.010 to 0.093) 0.02 0.139 (0.096 to 0.183) <0.001
Prebronchodilator FEV1 
— liters
0.12 (0.07 to 0.17) <0.001 0.02 (−0.03 to 0.07) 0.47 0.01 (−0.04 to 0.06) 0.60
Asthma Symptom Utility 
Index score
0.03 (0.01 to 0.05) 0.004 0.00 (−0.02 to 0.02) 0.77 0.04 (0.03 to 0.06) <0.001
Asthma Control 
Questionnaire score
−0.22 (−0.33 to −0.11) <0.001 −0.03 (−0.13 to 0.06) 0.49 −0.31 (−0.40 to −0.22) <0.001
Asthma Quality-of-Life 
Questionnaire score
0.15 (0.03 to 0.26) 0.01 0.05 (−0.06 to 0.15) 0.38 0.28 (0.18 to 0.38) <0.001
FEV1 after 4 puffs of 
albuterol — liters
0.02 (−0.01 to 0.05) 0.16 −0.02 (−0.05 to 0.01) 0.11 −0.05 (−0.08 to −0.03) <0.001
* Values in parentheses are 95% confidence intervals. Restricted maximum-likelihood estimates were determined for the treatment effects 
(the model-based change between the beginning and the end of each of the three treatment periods). Patients received tiotropium or sal-
meterol in addition to a low dose of beclomethasone or received a double dose of beclomethasone. The primary comparison was between 
tiotropium and double-glucocorticoid. The secondary comparison was between tiotropium and salmeterol. The comparison between salme-
terol and double-glucocorticoid was performed to determine whether the patients in the TALC study were similar to those in previous trials 
comparing long-acting beta-agonists with inhaled glucocorticoids. FEV1 denotes forced expiratory volume in 1 second, and PEF peak expira-
tory flow.
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14 during each 14-week treatment period. Out-
comes that were recorded on daily diary cards 
were averaged between visits, so that the week 0 
measurement represented the mean during the 
last 2 weeks of the run-in period or the 2 weeks 
of the washout period between treatments, the 
week 4 measurement represented the mean be-
tween week 0 and week 4, and so forth. Restrict-
ed maximum-likelihood estimates were deter-
mined for the treatment effects (the model-based 
change between week 0 and week 14) with the 
use of PROC MIXED of the SAS/STAT statistical-
analysis software, version 9.2 (SAS Institute). The 
null hypothesis of inferiority for the secondary 
hypothesis was rejected in favor of noninferior-
ity if the upper 97.5% confidence limit for the dif-
ference between salmeterol treatment and tiotro-
pium treatment was less than the prespecified 
bound (10.6 liters per minute for the morning PEF, 
0.07 for the proportion of asthma-control days, 
and 0.09 liters for the prebronchodilator FEV1).
The statistical analysis plans included an ex-
ploratory analysis to identify patients, among 
those who completed the trial, with certain pre-
specified responses with respect to the morning 
PEF, prebronchodilator FEV1, and asthma-control 
days.16,17 We defined a lung-function response 
as a relative increase in the morning PEF or FEV1 
of at least 7.5% and an asthma-control-day re-
sponse as a proportional increase of at least 0.10. 
Data regarding the morning PEF and asthma-
control days were collected daily; therefore, 2-week 
averages before baseline and at the end of the 
treatment period were used to characterize the 
response. In addition, using information from 
Lemanske and colleagues,21 we defined a three-
dimensional response as a positive response with 
respect to both lung function (either morning PEF 
or FEV1) and the number of asthma-control days, 
with no exacerbations of asthma. We defined a 
two-dimensional response as a positive response 
with respect to either lung function or the num-
ber of asthma-control days, with no asthma ex-
acerbations. These definitions were not prespeci-




Of the 210 study patients, 141 (67.1%) were women; 
59 (28.1%) were black, and 24 (11.4%) were His-
panic (Table 1, and Table S1 in the Supplementary 
Appendix). The mean baseline FEV1 before bron-
chodilation was 2.31±0.77 liters (71.5±14.9% of 
the predicted value), and the mean score on the 
Asthma Control Questionnaire was 1.64±0.73. The 
mean percentages of reversibility of airway ob-







25.8 (14.4 to 37.1) <0.001 6.4 (−4.8 to 17.5) 0.26 19.4 (9.4 to 29.4) <0.001
35.3 (24.6 to 46.0) <0.001 10.6 (−0.1 to 21.3) 0.05 24.7 (15.2 to 34.3) <0.001
−0.05 (−0.24 to 0.14) 0.63 0.04 (−0.13 to 0.22) 0.63 −0.09 (−0.27 to 0.09) 0.33
−0.11 (−0.16 to −0.06) <0.001 −0.04 (−0.09 to 0.01) 0.10 −0.07 (−0.12 to −0.02) 0.005
0.079 (0.019 to 0.140) 0.01 −0.009 (−0.070 to 0.053) 0.78 0.088 (0.028 to 0.148) 0.004
0.10 (0.03 to 0.17) 0.004 0.11 (0.04 to 0.18) 0.003 0.00 (−0.08 to 0.07) 0.89
0.03 (0.00 to 0.06) 0.09 −0.01 (−0.04 to 0.02) 0.38 0.04 (0.01 to 0.07) 0.005
−0.18 (−0.34 to −0.03) 0.02 0.09 (−0.04 to 0.23) 0.18 −0.28 (−0.41 to −0.15) <0.001
0.10 (−0.07 to 0.27) 0.24 −0.13 (−0.28 to 0.02) 0.09 0.23 (0.09 to 0.37) 0.002
0.04 (0.01 to 0.08) 0.01 0.07 (0.05 to 0.10) <0.001 −0.03 (−0.06 to 0.00) 0.06
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struction after four puffs of albuterol and ipratro-
pium bromide were 14.9±9.8% and 12.4±9.5%, re-
spectively. The mean morning PEF was 377.2±117.0 
liters per minute, and the proportion of asthma-
control days was 0.21±0.33 (2.97±4.64 days) dur-
ing the 2 weeks before randomization. Baseline 
values before each of the three active treatment 
periods were similar for the morning PEF (377.2± 
117.0, 383.9±117.6, and 383.0±115.0 liters per min-
ute, respectively) and FEV1 (2.31±0.77, 2.36±0.77, 
and 2.36±0.75 liters, respectively), whereas the pro-
portion of asthma-control days increased from 
0.21±0.33 before treatment period 1 to 0.34±0.40 
and 0.34±0.41 before treatment periods 2 and 3, 
respectively. Although minimal carryover effects 
between periods were observed for measures of 
lung function, an effect was seen for asthma-
control days (Table S2 in the Supplementary Ap-
pendix). Markers of inflammation at randomiza-
tion (exhaled nitric oxide and sputum eosinophils) 
were low at baseline and thereafter.
Primary Outcome
Patients receiving tiotropium had a morning PEF 
that was 25.8 liters per minute higher than that 
of patients receiving a double dose of glucocorti-
coid (95% confidence interval [CI], 14.4 to 37.1; 
P<0.001) (Table 2, and Table S3 in the Supplemen-
tary Appendix). Similar results favoring tiotropi-
um over a double glucocorticoid dose were ob-
tained for the evening PEF, with a difference of 
35.3 liters per minute (95% CI, 24.6 to 46.0; 
P<0.001); the prebronchodilator FEV1, with a dif-
ference of 0.10 liters (95% CI, 0.03 to 0.17; 
P = 0.004); the proportion of asthma-control days, 
with a difference of 0.079 (95% CI, 0.019 to 0.140; 
P = 0.01); score for daily symptoms, with a differ-
ence of −0.11 points (95% CI, −0.16 to −0.06; 
P<0.001); the score on the Asthma Control Ques-
tionnaire, with a difference of −0.18 points (95% 
CI, −0.34 to −0.03; P = 0.02); and the FEV1 after 
four puffs of albuterol, with a difference of 0.04 
liters (95% CI, 0.01 to 0.08; P = 0.01).
Secondary Outcomes
There were no significant differences between 
tiotropium treatment and salmeterol treatment 
with respect to the morning PEF, which was 
6.4 liters per minute higher among patients receiv-
ing tiotropium (95% CI, −4.8 to 17.5; P = 0.26); the 
evening PEF, with a difference of 10.6 liters per 
minute (95% CI, −0.1 to 21.3; P = 0.05); the propor-
tion of asthma control days, with a difference of 
−0.009 (95% CI, −0.070 to 0.053; P = 0.78); the 
score for daily symptoms, with a difference of 
−0.04 points (95% CI, −0.09 to 0.01; P = 0.10); the 
score on the Asthma Control Questionnaire, with 
a difference of 0.09 (95% CI, −0.04 to 0.23; P = 0.18); 
and a difference in the proportion of sputum eo-
sinophils of 0.20% (95% CI, −0.36 to 0.76; P = 0.49) 
(Table S3 in the Supplementary Appendix). The 
null hypothesis of inferiority was rejected in favor 
of the alternative hypothesis of noninferiority at 
the 0.025 significance level for the morning PEF, 
the prebronchodilator FEV1, and the proportion of 
asthma-control days. The prebronchodilator FEV1 
favored tiotropium, with an increase of 0.11 liters 
(95% CI, 0.04 to 0.18; P = 0.003), as did the FEV1 
after four puffs of albuterol, with an increase of 
0.07 liters (95% CI, 0.05 to 0.10; P<0.001).
Comparison of Salmeterol and Double-Dose 
Glucocorticoid
This comparison was performed to determine 
whether the patients in the TALC study were sim-
ilar to those in previous trials comparing LABA 
with an inhaled glucocorticoid.3,4 Salmeterol was 
superior to the double dose of beclomethasone 
with respect to the morning PEF, with a between-
group difference of 19.4 liters per minute (95% 
CI, 9.4 to 29.4; P<0.001); the evening PEF, with a 
difference of 24.7 liters per minute (95% CI, 15.2 
to 34.3; P<0.001); the proportion of asthma-con-
trol days, with a difference of 0.088 (95% CI, 0.028 
to 0.148; P = 0.004); the daily-symptom score, 
with a difference of −0.07 units (95% CI, −0.12 to 
−0.02; P = 0.005); the score on the Asthma Control 
Questionnaire, with a difference of −0.28 (95% CI, 
−0.41 to −0.15; P<0.001); the score on the Asth-
ma Symptom Utility Index, with a difference of 
0.04 units (95% CI, 0.01 to 0.07; P = 0.005); and 
the score on the Asthma Quality-of-Life Question-
naire, with a difference of 0.23 units (95% CI, 
0.09 to 0.37; P = 0.002). A summary of changes in 
the morning and evening PEF, the prebronchodi-
lator FEV1, and the proportion of asthma-control 
days (per 2-week period) according to treatment 
period is shown in Figure 3.
Exploratory Response Analyses
The proportions of patients with a two-dimension-
al response or a three-dimensional response to the 
various treatments are shown in Table 3. A total 
of 31.3% of patients had a two-dimensional re-
sponse to all three treatment regimens, whereas 
9.4% had no such response to any of them. A small 
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proportion of patients (5.6 to 8.8%) had a response 
to only one treatment. Two-dimensional respons-
es occurred in 66.3% of patients receiving tiotro-
pium, 53.1% of those receiving double-glucocor-
ticoid, and 70.6% of those receiving salmeterol.
Asthma Exacerbations and Adverse Events
An asthma exacerbation occurred in 9 patients 
receiving tiotropium, 16 receiving double-gluco-
corticoid, and 5 receiving salmeterol; the respec-
tive numbers of patients with asthma exacerba-
tions for which oral or intravenous glucocorticoids 
were administered were 7, 13, and 5. Patients re-
ceiving the double dose of beclomethasone had 
the highest numbers of unscheduled visits for 
asthma symptoms (2 for tiotropium, 6 for dou-
ble-glucocorticoid, and 2 for salmeterol), emer-
gency room visits (2, 4, and 1, respectively), and 
events for which urgent care was needed (4, 9, 
and 3, respectively). Two hospitalizations for asth-
ma occurred, 1 among patients receiving tiotro-
pium and 1 among those receiving double-gluco-
corticoid. Reasons for withdrawal from the trial 
(7 for tiotropium, 14 for double-glucocorticoid, 
and 15 for salmeterol) are provided in Table S4 in 
the Supplementary Appendix.
A total of 12 serious adverse events involving 
hospitalization or an emergency room visit oc-
curred: 3 among patients receiving tiotropium 
(2 hospitalizations for pneumonia and 1 for a 
fractured radius), 4 among those receiving dou-
ble-glucocorticoid (1 hospitalization for spinal 
stenosis surgery, 1 for atypical chest pain, 1 for 
transient global amnesia, and 1 for pneumonia), 
4 among those receiving salmeterol (1 hospital-











































































































Figure 3. Primary and Secondary Outcomes.
Shown are the mean differences among patients receiving tiotropium, those receiving double-glucocorticoid, and those receiving sal-
meterol with respect to the morning peak expiratory flow (PEF) (Panel A), the evening PEF (Panel B), the prebronchodilator forced expi-
ratory volume in 1 second (FEV1) (Panel C), and the proportion of asthma-control days per 14-day period (Panel D). The I bars indicate 
95% confidence intervals.
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hysterectomy for endometrial carcinoma, 1 hos-
pitalization for hysterectomy to remove fibroids, 
1 hospitalization for knee-replacement surgery, 
and 1 emergency room visit for stridor after in-
gestion of orange juice), and 1 during the single-
dose-glucocorticoid run-out period (hospitaliza-
tion for tonsillitis).
Discussion
We report two findings with implications for the 
treatment of asthma in adults. First, our study 
shows that the use of tiotropium was superior to 
a doubling of the dose of an inhaled glucocorti-
coid for patients whose symptoms were inade-
quately controlled while they were receiving in-
haled beclomethasone alone at a dose of 80 μg 
twice a day. Second, among patients in our study 
who were similar to those in trials showing the 
clinical efficacy of LABA therapy,3,4 tiotropium was 
noninferior to salmeterol on the basis of predefined 
criteria, a finding that meets the standards es-
tablished in the FDA’s draft guidance for indus-
try on noninferiority clinical trials.22
Our selection of the morning PEF as the pri-
mary outcome might attract criticism, even though 
the trial was adequately powered and analyzed 
for another key patient-centric outcome, the pro-
portion of asthma-control days. Our rationale was 
that pulmonary function remains an important 
element of asthma control, improvements in the 
PEF were similar to those in previous Asthma 
Clinical Research Network trials comparing an 
active treatment with placebo,23,24 and improve-
ments in pulmonary function that were induced 
by tiotropium were accompanied by improvements 
in both asthma symptoms and the proportion of 
asthma-control days.
We did not evaluate whether increasing the 
dose of an inhaled glucocorticoid by more than 
a factor of two would provide an increased bene-
fit. Although an increase in the dose of an in-
haled glucocorticoid by a factor of four has been 
reported to reduce asthma exacerbations,25 low 
doses of an inhaled glucocorticoid have been re-
ported to provide a benefit equivalent to that of 
a high dose with respect to measures of asthma 
control,26 the outcomes that we studied. In addi-
tion, combinations of inhaled glucocorticoids and 
LABA therapy have been reported to provide su-
perior asthma control, as compared with an in-
creased dose of an inhaled glucocorticoid, even 
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Although the effects of tiotropium and salmet-
erol were similar in general, measures of the 
prebronchodilator FEV1 favored tiotropium. The 
small decrease in FEV1 after four puffs of albuterol 
among patients receiving salmeterol (0.05 liters) 
suggests possible tachyphylaxis to the effect of 
an additional dose of a beta-agonist, a finding 
not observed in the tiotropium group (with an 
increase of 0.02 liters). At baseline, the short-
term response to four puffs of albuterol (revers-
ibility of airway obstruction of 14.9%) was simi-
lar to the response to four puffs of ipratropium 
(reversibility of 12.4%), which suggests that ip-
ratropium could be considered as an acute bron-
chodilator for patients with asthma, as was 
shown in the Asthma Clinical Research Net-
work’s Long-Acting Beta Agonist Response by 
Genotype (LARGE) trial (NCT00200967).28
The exploratory response analysis provides 
several insights. In evaluating the response to 
treatment on the basis of the very stringent three-
dimensional measurement, we found that only 
36% of patients receiving a bronchodilator and an 
inhaled glucocorticoid had such a response, as 
compared with less than 10% of patients receiving 
a double dose of an inhaled glucocorticoid (Ta-
ble 3). These data could be used to examine how 
treatment responses are distributed in a popula-
tion of patients with asthma. For example, if the 
less stringent two-dimensional criteria were ap-
plied and if the goal were to treat the greatest 
number of patients with a drug to which they had 
a response and to maximize the use of inhaled 
glucocorticoids, 53.1% of patients would be treat-
ed with a double dose of an inhaled glucocorti-
coid, 8.8% with tiotropium plus an inhaled glu-
cocorticoid, and 8.1% with salmeterol plus an 
inhaled glucocorticoid, leaving 20.6% to be treat-
ed with either one of the bronchodilators com-
bined with a low-dose inhaled glucocorticoid and 
9.4% who had no response to any treatment.
On the basis of our study’s design, we evalu-
ated only a small number of patients, with no 
treatment lasting longer than 14 weeks. Since we 
could not examine either the rate of asthma ex-
acerbations or long-term safety issues, our find-
ings cannot be considered clinically directive. 
Additional studies that have sufficient statistical 
power to evaluate exacerbations and safety events 
are required to further establish the clinical ef-
ficacy of tiotropium. However, our data establish 
clinical equipoise to study larger cohorts of adults 
for longer periods of time with tiotropium as a 
therapy for asthma control.
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